The generic injectables market in Asia Pacific is expected to grow from US$ 26,606.06 million in 2021 to US$ 55,751.62 million by 2028; it is estimated to grow at a CAGR of 11.1% from 2021 to 2028.
The patents of branded injectables in several countries are likely to expire in the upcoming years, offering numerous remunerative opportunities to the generic injectables manufacturers. The shortage of branded medicines in India and the expiry of branded drug patents have prompted generic injectable manufacturers to introduce advanced drug delivery systems, including self-injection devices. Biological E Limited, an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio with the addition of 20 routine and injectable products. Thus, generic injectables companies are tapping regulated markets and exploring other markets to generate incomes and establish stable revenue streams. Additionally, manufacturers in the generic injectables market are becoming future-ready by maintaining adequate supply chains to prevent vulnerabilities, such as those caused by the COVID-19 outbreak. Zydus Cadila is significantly reducing the price of its generic version of Remdesivir, namely Remdac. Thus, the nearing expiry of patent validity of branded drugs is likely to provide significant opportunities to generic drug manufacturers, including the companies offering generic injectables.Asia Pacific Generic Injectables Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Generic Injectables Market Segmentation
The Asia Pacific generic injectables market is segmented into product type, container type, application, route of administration, and country. Based on product type, the market has been segmented into large molecule injectable and small molecule injectable. In 2020, the large molecule injectable segment held a larger market share. In terms of container type, the market has been categorized into vials, premix, prefilled syringes, ampoules, and others. In 2020, the vials segment held the largest share of the Asia Pacific generic injectables market. Based on application, the market has been segmented into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2020, the oncology segment held the largest share of the market. Based on route of administration, the market has been categorized into intravenous, intramuscular, subcutaneous, and others. In 2020, the intravenous segment held the largest market share. Based on country, the Asia Pacific generic injectables market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China contributed a substantial share in 2020.
AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.; Pfizer Inc.; and Viatris Inc are among the leading companies in the Asia-Pacific generic injectables market.